PHILADELPHIA--(BUSINESS WIRE)-- Lawyers on behalf of tens of thousands of ovarian cancer victims are calling on Johnson & Johnson (NYSE: JNJ) to end its “war of attrition against cancer victims.” On ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback